{"id":34898,"date":"2026-03-30T17:52:00","date_gmt":"2026-03-30T12:22:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=34898"},"modified":"2026-03-30T14:22:50","modified_gmt":"2026-03-30T08:52:50","slug":"avlayah-for-hunter-syndrome","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/avlayah-for-hunter-syndrome","title":{"rendered":"Denali\u2019s AVLAYAH Win for Hunter Syndrome Marks Turning Point for Rare Disease Innovation"},"content":{"rendered":"\n<p><strong><em>Summary<\/em><\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><em>AVLAYAH (tividenofusp alfa\u2011eknm) has received FDA accelerated approval as the first Hunter syndrome therapy specifically designed to treat neurologic manifestations by crossing the blood\u2013brain barrier.<\/em><\/li>\n\n\n\n<li><em>The drug uses Denali\u2019s TransportVehicle platform to fuse the IDS enzyme with a transferrin\u2011receptor\u2013targeting component, enabling enzyme delivery to both brain and peripheral tissues with a single weekly IV infusion.<\/em><\/li>\n\n\n\n<li><em>Approval is based on Phase 1\/2 data showing deep reductions (around 90%) in cerebrospinal fluid heparan sulfate and normalization of this key biomarker in most treated children, a change judged reasonably likely to predict neurologic benefit.<\/em><\/li>\n\n\n\n<li><em>Continued approval depends on positive results from the ongoing Phase 2\/3 COMPASS trial, which compares AVLAYAH against idursulfase and is designed to confirm meaningful cognitive, behavioral, and functional benefits in children with Hunter syndrome.<\/em><\/li>\n<\/ul>\n\n\n\n<p>AVLAYAH\u2019s U.S. approval marks a watershed moment for Hunter syndrome, delivering the first therapy specifically engineered to reach the brain and target the disease\u2019s devastating neurologic manifestations in children. It also breaks a recent streak of rare-disease rejections at the FDA, sending an important signal about how regulators may handle innovative treatments built on strong biomarker science in ultra\u2011rare conditions.<\/p>\n\n\n\n<p>Hunter syndrome (mucopolysaccharidosis type II, MPS II) is a rare X\u2011linked <a href=\"https:\/\/www.delveinsight.com\/blog\/lysosomal-storage-disorders-rare-diseases-impacting-millions\">lysosomal storage disorder<\/a> that primarily affects boys and is thought to impact roughly <strong>500 individuals <\/strong>in the U.S. and about <strong>2,000<\/strong> worldwide. Mutations in the iduronate 2\u2011sulfatase (IDS) gene lead to deficient IDS enzyme activity and accumulation of glycosaminoglycans (GAGs) such as heparan sulfate and dermatan sulfate, causing progressive multi\u2011organ damage, including to the brain. Children can develop cognitive and behavioral decline, hearing loss, motor impairment, joint stiffness, and organ dysfunction, often beginning in early childhood.<\/p>\n\n\n\n<p>Until now, <strong>Takeda\u2019s idursulfase (ELAPRASE) <\/strong>was the only FDA\u2011approved treatment, providing systemic enzyme replacement but failing to cross the blood\u2013brain barrier (BBB), and therefore offering no direct benefit for neurologic symptoms. For families watching children slowly lose speech, mobility, and cognition, the therapeutic landscape has long felt stagnant and painfully inadequate.<\/p>\n\n\n\n<p>On March 25, 2026, the FDA granted accelerated approval to AVLAYAH (tividenofusp alfa\u2011eknm), an intravenous enzyme replacement therapy from <strong>Denali Therapeutics<\/strong>. AVLAYAH is indicated for the treatment of neurologic manifestations of Hunter syndrome when initiated in presymptomatic or symptomatic pediatric patients weighing at least 5 kg, before they reach advanced neurologic impairment.<\/p>\n\n\n\n<p>This is the first new FDA\u2011approved <a href=\"https:\/\/www.delveinsight.com\/report-store\/hunter-syndrome-market\">treatment option for Hunter syndrome<\/a> in nearly 20 years and the first product approved that is explicitly designed to address the disease\u2019s neurologic complications. It is also the first FDA\u2011approved biotherapeutic that uses the transferrin receptor to cross the blood\u2013brain barrier, inaugurating a new class of brain\u2011penetrant biologics.<\/p>\n\n\n\n<p>The approval carries standard rare\u2011disease incentives and labels: AVLAYAH received <strong>Breakthrough Therapy, Fast Track, Orphan Drug, and Rare Pediatric Disease designations<\/strong>, and Denali was awarded a <strong>Rare Pediatric Disease Priority Review Voucher<\/strong> alongside approval.<\/p>\n\n\n\n<p>AVLAYAH is built on <strong>Denali\u2019s proprietary TransportVehicle (TV) platform<\/strong>, designed to shuttle large biologics into the brain by exploiting natural transport receptors on the BBB. The molecule fuses the IDS enzyme to an engineered Fc domain that binds the transferrin receptor (TfR) on endothelial cells lining the brain\u2019s vasculature.<\/p>\n\n\n\n<p>Once infused, AVLAYAH binds TfR, is ferried across the BBB via receptor\u2011mediated transcytosis, and then engages mannose\u20116\u2011phosphate receptors on cells, delivering the IDS enzyme into lysosomes, where it can break down accumulated GAGs. Because TfR is widely expressed, the construct is expected to deliver IDS not only to the central nervous system but also to peripheral tissues, offering whole\u2011body and brain exposure in a single weekly infusion.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"444\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/AVLAYAH-Development-Timeline-1024x444.webp\" alt=\"\" class=\"wp-image-34903\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/AVLAYAH-Development-Timeline-1024x444.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/AVLAYAH-Development-Timeline-300x130.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/AVLAYAH-Development-Timeline-150x65.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/AVLAYAH-Development-Timeline-768x333.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/AVLAYAH-Development-Timeline-1536x666.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/AVLAYAH-Development-Timeline.webp 1920w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>In contrast, legacy ERT, such as ELAPRASE, remains largely outside the CNS, improving somatic symptoms but leaving the neurologic trajectory largely unchanged. AVLAYAH\u2019s brain\u2011penetrant design is therefore central to the excitement around its potential to alter the natural history of severe, neuronopathic MPS II.<\/p>\n\n\n\n<p>The FDA\u2019s decision rests on robust <strong>Phase 1\/2 biomarker data<\/strong> rather than fully mature clinical outcomes, in keeping with the accelerated approval pathway. In an international, multi\u2011center open\u2011label trial, 47 children with Hunter syndrome (both ERT\u2011na\u00efve and previously treated, ages 0.3 to 13 years) received weekly AVLAYAH infusions.<\/p>\n\n\n\n<p>The primary objective was safety and tolerability, while secondary endpoints focused on central and peripheral pharmacodynamic effects, including heparan sulfate levels in cerebrospinal fluid (CSF) and urine, adaptive behavior measures, and liver volume. By week 24, AVLAYAH produced a 91% reduction in CSF heparan sulfate from baseline (95% CI: 89\u201392%), a magnitude of effect the FDA concluded was \u201creasonably likely to predict clinical benefit\u201d on neurologic outcomes.<\/p>\n\n\n\n<p>Notably, 93% of patients (41 of 44) had CSF heparan sulfate levels within the range observed in <a href=\"https:\/\/www.delveinsight.com\/report-store\/hunter-syndrome-epidemiology-forecast\">individuals without Hunter syndrome<\/a> by week 24, suggesting normalization of this key disease biomarker in the vast majority of treated children. These data were compelling enough to earn publication in <strong>The New England Journal of Medicine<\/strong> on January 1, 2026, underscoring the scientific interest in this approach.<\/p>\n\n\n\n<p>From a safety standpoint, the most common adverse events were infusion\u2011associated reactions, such as fever, chills, flushing, rash, and gastrointestinal symptoms, consistent with other ERTs. Three serious but manageable adverse events were reported in earlier datasets, and one patient discontinued treatment in part due to infusion reactions. Overall, the program met its predefined safety and tolerability expectations.<\/p>\n\n\n\n<p>Despite its promise, AVLAYAH carries important risks that will shape how clinicians introduce the drug into practice. The U.S. prescribing information includes warnings for hypersensitivity reactions, including life\u2011threatening anaphylaxis, which have occurred both early and after multiple doses, with symptoms such as wheezing, hypotension, hives, vomiting, and swelling of the lips or tongue.<\/p>\n\n\n\n<p>Infusion\u2011associated reactions can occur during or within 24 hours of dosing and may include chills, fever, flushing, rash, low blood pressure, tachycardia, respiratory symptoms, and gastrointestinal complaints, sometimes necessitating premedication, slowing or pausing the infusion, or stopping treatment in severe cases. Anemia has been observed and may require periodic monitoring of hemoglobin, while membranous nephropathy has been reported in at least one patient, prompting recommendations for ongoing renal function surveillance.<\/p>\n\n\n\n<p>The label states that AVLAYAH is not recommended in combination with other enzyme replacement therapies, leaving physicians to consider switching rather than layering therapies for patients already on Elaprase. Overall, the safety profile appears clinically manageable in experienced hands but will require structured infusion protocols and careful monitoring, especially in children with underlying cardiac or pulmonary compromise.<\/p>\n\n\n\n<p>Continued FDA approval is contingent on verification of clinical benefit in the ongoing <strong>Phase 2\/3 COMPASS trial<\/strong>, which is already more than 95% enrolled according to regulators. This randomized study compares AVLAYAH head\u2011to\u2011head with idursulfase in children and young adults with Hunter syndrome, using a 2:1 randomization schema in favor of AVLAYAH.<\/p>\n\n\n\n<p>COMPASS is designed to capture cognitive, adaptive behavior, and functional outcomes across the <a href=\"https:\/\/www.delveinsight.com\/report-store\/mucopolysaccharidosis-ii-market\">MPS II spectrum<\/a>, aiming to translate biomarker normalization into measurable preservation of development, behavior, and quality of life. Denali intends to use COMPASS as the backbone for global regulatory submissions, and the European Medicines Agency has already granted <strong>Priority Medicines (PRIME) designation <\/strong>to tividenofusp alfa, underscoring its potential impact in an area of high unmet need.<\/p>\n\n\n\n<p>Until full clinical data mature, the field will watch closely to see whether deep reductions in CSF heparan sulfate truly correlate with slowed neurocognitive decline and improved daily functioning in real\u2011world children.<\/p>\n\n\n\n<p>AVLAYAH\u2019s approval lands against the backdrop of a turbulent period for rare\u2011disease drug developers, marked by a series of high\u2011profile FDA rejections and shifting expectations around evidence standards. Earlier in 2026, the agency issued a complete response letter to REGENXBIO\u2019s <a href=\"https:\/\/www.delveinsight.com\/report-store\/hunter-syndrome-market\">Hunter syndrome gene therapy<\/a>, citing concerns about the use of natural\u2011history controls, eligibility criteria, and biomarker validation, despite prior dialogue that suggested the design might be acceptable.<\/p>\n\n\n\n<p>Those decisions fueled anxiety that regulators were becoming less flexible on rare\u2011disease programs, particularly in ultra\u2011rare, pediatric neurodegenerative settings where large randomized trials can be difficult or impossible. In that context, AVLAYAH\u2019s accelerated approval based on a rigorously characterized surrogate endpoint is being viewed as a \u201cwelcome positive\u201d and a sign that the FDA can still exercise appropriate flexibility when the totality of biomarker, mechanistic, and clinical data is compelling.<\/p>\n\n\n\n<p>In conclusion, AVLAYAH\u2019s approval is not the end of the story; it is a beginning. The COMPASS trial must still demonstrate that biomarker gains translate into meaningful clinical benefits, regulators outside the U.S. must weigh the data under their own frameworks, and payers will have to decide how to reimburse a high\u2011cost, first\u2011in\u2011class therapy for an ultra\u2011rare disease.<\/p>\n\n\n\n<p>But from a scientific and regulatory standpoint, the precedent is powerful: an engineered enzyme replacement therapy that crosses the blood\u2013brain barrier, normalizes a central biomarker in the vast majority of treated children, and wins accelerated approval in an otherwise hostile rare\u2011disease climate. For Hunter syndrome and for the broader field of neuro\u2011rare disorders, AVLAYAH\u2019s approval is more than a label; it is a signal that with the right science and advocacy, the bar for meaningful progress, brain included, can be cleared.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/hunter-syndrome-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/Hunter-Syndrome-Market-Outlook-1024x194.webp\" alt=\"Hunter Syndrome Market Outlook\" class=\"wp-image-34902\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/Hunter-Syndrome-Market-Outlook-1024x194.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/Hunter-Syndrome-Market-Outlook-300x57.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/Hunter-Syndrome-Market-Outlook-150x28.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/Hunter-Syndrome-Market-Outlook-768x145.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/Hunter-Syndrome-Market-Outlook-1536x291.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/Hunter-Syndrome-Market-Outlook.webp 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Summary AVLAYAH\u2019s U.S. approval marks a watershed moment for Hunter syndrome, delivering the first therapy specifically engineered to reach the brain and target the disease\u2019s devastating neurologic manifestations in children. It also breaks a recent streak of rare-disease rejections at the FDA, sending an important signal about how regulators may handle innovative treatments built on [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":34900,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[22936,22938,303,12926,12925,22937],"industry":[17225],"therapeutic_areas":[17238,17234],"class_list":["post-34898","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-avlayah","tag-elaprase","tag-hunter-syndrome","tag-hunter-syndrome-market","tag-hunter-syndrome-pipeline","tag-hunter-syndrome-treatment","industry-pharmaceutical","therapeutic_areas-genetic-disorders","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Denali\u2019s AVLAYAH Sparks New Hope in Hunter Syndrome<\/title>\n<meta name=\"description\" content=\"Denali&#039;s AVLAYAH (tividenofusp alfa\u2011eknm) has received FDA accelerated approval as first Hunter syndrome therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/avlayah-for-hunter-syndrome\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Denali\u2019s AVLAYAH Sparks New Hope in Hunter Syndrome\" \/>\n<meta property=\"og:description\" content=\"Denali&#039;s AVLAYAH (tividenofusp alfa\u2011eknm) has received FDA accelerated approval as first Hunter syndrome therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/avlayah-for-hunter-syndrome\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-30T12:22:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/avlayah-for-hunter-syndrome.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Denali\u2019s AVLAYAH Sparks New Hope in Hunter Syndrome","description":"Denali's AVLAYAH (tividenofusp alfa\u2011eknm) has received FDA accelerated approval as first Hunter syndrome therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/avlayah-for-hunter-syndrome","og_locale":"en_US","og_type":"article","og_title":"Denali\u2019s AVLAYAH Sparks New Hope in Hunter Syndrome","og_description":"Denali's AVLAYAH (tividenofusp alfa\u2011eknm) has received FDA accelerated approval as first Hunter syndrome therapy.","og_url":"https:\/\/www.delveinsight.com\/blog\/avlayah-for-hunter-syndrome","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2026-03-30T12:22:00+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/avlayah-for-hunter-syndrome.webp","type":"image\/webp"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/avlayah-for-hunter-syndrome","url":"https:\/\/www.delveinsight.com\/blog\/avlayah-for-hunter-syndrome","name":"Denali\u2019s AVLAYAH Sparks New Hope in Hunter Syndrome","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/avlayah-for-hunter-syndrome#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/avlayah-for-hunter-syndrome#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/avlayah-for-hunter-syndrome.webp","datePublished":"2026-03-30T12:22:00+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Denali's AVLAYAH (tividenofusp alfa\u2011eknm) has received FDA accelerated approval as first Hunter syndrome therapy.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/avlayah-for-hunter-syndrome"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/avlayah-for-hunter-syndrome#primaryimage","url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/avlayah-for-hunter-syndrome.webp","contentUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/avlayah-for-hunter-syndrome.webp","width":466,"height":284,"caption":"avlayah-for-hunter-syndrome"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/avlayah-for-hunter-syndrome-300x183.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">AVLAYAH<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">ELAPRASE<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Hunter syndrome<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Hunter Syndrome Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Hunter Syndrome Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Hunter Syndrome Treatment<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AVLAYAH<\/span>","<span class=\"advgb-post-tax-term\">ELAPRASE<\/span>","<span class=\"advgb-post-tax-term\">Hunter syndrome<\/span>","<span class=\"advgb-post-tax-term\">Hunter Syndrome Market<\/span>","<span class=\"advgb-post-tax-term\">Hunter Syndrome Pipeline<\/span>","<span class=\"advgb-post-tax-term\">Hunter Syndrome Treatment<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 months ago","modified":"Updated 2 months ago"},"absolute_dates":{"created":"Posted on Mar 30, 2026","modified":"Updated on Mar 30, 2026"},"absolute_dates_time":{"created":"Posted on Mar 30, 2026 5:52 pm","modified":"Updated on Mar 30, 2026 2:22 pm"},"featured_img_caption":"avlayah-for-hunter-syndrome","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/34898","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=34898"}],"version-history":[{"count":2,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/34898\/revisions"}],"predecessor-version":[{"id":34904,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/34898\/revisions\/34904"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/34900"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=34898"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=34898"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=34898"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=34898"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=34898"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}